Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedrine bill

This article was originally published in The Tan Sheet

Executive Summary

NDMA testifies Dec. 15 against SB 564, a Wisconsin state bill that would classify ephedrine as a Schedule III controlled substance in that state. A national bill (HR 3216), NDMA noted, would remove the "exemption from the record-keeping and reporting requirements of the Chemical Diversion and Trafficking Act for drugs containing ephedrine as the only active medicinal ingredient." NDMA maintained to the Wisconsin Senate and Judiciary Committee that state legislation "should be deferred until the federal law can be signed by the President and implemented by the Drug Enforcement Administration." HR 3216 was signed into law by President Clinton on Dec. 17
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082299

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel